Background/Aim: Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma. Patients and Methods: The medical records of 53 consecutive patients were reviewed and analyzed. Results: Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (7.5%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-to-lymphocyte ratio <156 before nivolumab treatment (p=0.006). Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma.

中文翻译：

---

转移性肾细胞癌患者接受纳武单抗治疗后免疫相关不良事件与临床结局的关系

背景/目的：免疫相关不良事件 (irAE) 与免疫检查点抑制剂在黑色素瘤和非小细胞肺癌患者中的疗效相关。因此，我们评估了 irAE 与纳武单抗对转移性肾细胞癌疗效之间的关系。患者和方法：回顾和分析53名连续患者的病历。结果：与没有 irAE 的患者相比，在任何时间出现 irAE 的患者的中位总生存期显着更好（p=0.013）。我们在 53 名患者中的 24 名 (45.3%) 中发现了 irAE，其中包括 4 名发生 3 级事件的患者 (7.5%)。多变量分析还显示，在纳武单抗治疗前，irAE 发生的危险因素与血小板与淋巴细胞比率 <156 呈正相关（p = 0.006）。结论：